KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Non-Current Liabilities (2016 - 2022)

Historic Total Non-Current Liabilities for Inovio Pharmaceuticals (INO) over the last 14 years, with Q4 2022 value amounting to $126.2 million.

  • Inovio Pharmaceuticals' Total Non-Current Liabilities rose 3107.64% to $126.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $126.2 million, marking a year-over-year increase of 3107.64%. This contributed to the annual value of $126.2 million for FY2022, which is 3107.64% up from last year.
  • According to the latest figures from Q4 2022, Inovio Pharmaceuticals' Total Non-Current Liabilities is $126.2 million, which was up 3107.64% from $124.6 million recorded in Q3 2022.
  • In the past 5 years, Inovio Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $161.7 million in Q2 2022 and a low of $36.9 million during Q3 2018
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $102.4 million (2019), whereas its average is $96.7 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 20067.3% in 2019 and then crashed by 4327.24% in 2021.
  • Inovio Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $44.0 million in 2018, then skyrocketed by 194.88% to $129.7 million in 2019, then crashed by 39.43% to $78.6 million in 2020, then rose by 22.51% to $96.3 million in 2021, then surged by 31.08% to $126.2 million in 2022.
  • Its last three reported values are $126.2 million in Q4 2022, $124.6 million for Q3 2022, and $161.7 million during Q2 2022.